Bone growth during rapamycin therapy in young rats
Open Access
- 13 January 2009
- journal article
- Published by Springer Nature in BMC Pediatrics
- Vol. 9 (1) , 3
Abstract
Rapamycin is an effective immunosuppressant widely used to maintain the renal allograft in pediatric patients. Linear growth may be adversely affected in young children since rapamycin has potent anti-proliferative and anti-angiogenic properties.Keywords
This publication has 27 references indexed in Scilit:
- Bone growth during daily or intermittent calcitriol treatment during renal failure with advanced secondary hyperparathyroidismKidney International, 2007
- Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3‐E1 cells and primary mouse bone marrow stromal cellsJournal of Cellular Biochemistry, 2007
- Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF‐1 Alpha/VEGF SignalingIUBMB Life, 2007
- Bone elongation in rats with renal failure and mild or advanced secondary hyperparathyroidismKidney International, 2004
- Linking Hematopoiesis to Endochondral Skeletogenesis through Analysis of Mice Transgenic for Collagen XThe American Journal of Pathology, 2002
- Osteoblastic Differentiation Is Enhanced by Rapamycin in Rat Osteoblast-like Osteosarcoma (ROS 17/2.8) CellsBiochemical and Biophysical Research Communications, 1998
- TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-RapamycinJournal of Biological Chemistry, 1995
- Rapamycin: A bone sparing immunosuppressant?Journal of Bone and Mineral Research, 1995
- Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in ratsCalcified Tissue International, 1993
- Differential expression of insulin-like growth factor-I (IGF-I) and IGF- II messenger ribonucleic acid in growing rat boneEndocrinology, 1993